BioSpace News Archive

The Lewy Body Dementia Association and Acadia Pharmaceuticals Inc. announced an exclusive partnership on the production and release of a disease education adaptation of the new film Robin’s Wish©, a documentary detailing the late actor Robin Williams’ courageous battle with the neurodegenerative disorder, Lewy body dementia.

Ra Medical Systems, Inc. (NYSE: RMED), a medical device company focused on commercializing excimer laser systems to treat vascular and dermatological diseases, announces enrollment of the 10 th subject in its pivotal clinical trial to evaluate the safety and effectiveness of the DABRA excimer laser system as an atherectomy device for the treatment of peripheral arterial disease (PAD). “Patient screening and enroll

Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2020 results on Tuesday, November 10, 2020.

Phase 2 clinical trials of Abivertinib now cleared to proceed in both Brazil and the U.S. Studies are complementary and address both dose duration and disease stage Rapid enrollment expected for both geographies SAN DIEGO, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced receipt of clearance from the Brazilian regulatory agency (ANVISA) to proceed with a Phase 2 clinical trial of Abivertinib

Revenue surges 47.9% compared with the first half of 2019 at €5.9m Order backlog up 40% over six months to €53.6m Cash and cash equivalents of €19.4m SOPHIA ANTIPOLIS, France--( BUSINESS WIRE )-- Regulatory News: Median Technologies (Paris:ALMDT), The Imaging Phenomics Company®, today announced its results for the first half of 2020. On October 12, 2020, the Board of Directors of Median Technologies approved the consolidated fi

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company has entered into a loan agreement with the European Investment Bank (EIB), granting the company access to an unsecured loan facility of up to €40 M. The loan may be used to further support the clinical development of melflufen, and the company’s tran

In lieu of an in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

Alessa Therapeutics, Inc., a privately held drug development company developing an innovative and proprietary localized drug delivery technology for the treatment of prostate disease, announced the enrollment of the first patient in the company’s Biolen-PC clinical study.

SI-BONE, Inc., a Silicon Valley-based medical device company focused on the development of implantable devices used in the surgical treatment of the sacropelvic anatomy, announced that it has commenced an underwritten public offering of 3,190,053 shares of its common stock.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced the grant of inducement awards to 11 new employees.